NASDAQ: OXBR

OXBRIDGE RE HOLDINGS Ltd

CIK 0001584831 · SIC 6331 · Fire, Marine & Casualty Insurance

Micro Revenue $3M Assets $20M as of Nov 15, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.

10-Q Filed Nov 9, 2026 · Period ending Sep 30, 2026

Summary not yet generated.

8-K Filed Nov 9, 2026 · Period ending Nov 9, 2026

Summary not yet generated.

Partner

Trade OXBR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Aug 13, 2026 · Period ending Aug 13, 2026

Summary not yet generated.

10-Q Filed Aug 13, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Jun 22, 2026 · Period ending Jun 22, 2026

Summary not yet generated.

424B5 Filed Jun 22, 2026 Red flag

Oxbridge Re Holdings launches at-the-market offering of up to $1.68 million at $1.03 per share

4 material changes detected. Sign up free to read the summary.

8-K Filed Jun 16, 2026 · Period ending Jun 16, 2026

Summary not yet generated.

10-Q Filed May 11, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

8-K Filed May 11, 2026 · Period ending May 11, 2026

Summary not yet generated.

10-K/A Filed Apr 6, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

8-K Filed Mar 30, 2026 · Period ending Mar 30, 2026

Summary not yet generated.

10-K Filed Mar 30, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 6, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

424B5 Filed Sep 16, 2025

Summary not yet generated.

424B5 Filed Jul 10, 2025

Summary not yet generated.

10-K Filed Mar 26, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Nov 9, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Consolidated Statements of Operations (Unaudited)

(expressed in thousands of U.S. Dollars, except per share amounts)

Description Three months ended September 30, 2026 Three months ended September 30, 2025 Nine months ended September 30, 2026 Nine months ended September 30, 2025
Revenue
Assumed premiums - - 314 2,222
Change in unearned premiums reserve 86 555 696 (490)
Net premiums earned 86 555 1,010 1,732
SurancePlus management fee income - - 501 1
Net investment and other income 175 79 312 251
Realized gain on other investments - - - 35
Unrealized loss on other investments - - - (20)
Change in fair value of equity securities - 11 - 2
Total revenue 261 645 1,823 2,001
Expenses
Losses and loss adjustment expenses - - - 2,293
Policy acquisition costs and underwriting expenses 9 61 114 191
General and administrative expenses 638 754 1,763 2,515
Total expenses 647 815 1,877 4,999
(Loss) before income / loss attributable to tokenholders and non-controlling interests (386) (170) (54) (2,998)
(Income) loss attributable to tokenholders (3) (2) (5) 697
(Loss) before (income) loss attributable to non-controlling interests (389) (172) (59) (2,301)
(Income) loss attributable to non-controlling interests (32) (15) (164) 102
Net loss attributable to ordinary shareholders (421) (187) (223) (2,199)
Loss per share attributable to ordinary shareholders
Basic and Diluted (0.05) (0.02) (0.03) (0.30)
Weighted-average shares outstanding
Basic and Diluted 8,124,949 7,664,122 8,017,781 7,297,044

Consolidated Balance Sheets

(expressed in thousands of U.S. Dollars, except per share and share amounts)

Description At September 30, 2026 (Unaudited) At December 31, 2025
Assets
Cash and cash equivalents 4,137 268
Restricted cash and cash equivalents (Cat Re token program) 3,303 6,708
Restricted cash and cash equivalents (HCI 2026 token program) 12,125 -
Premiums receivable 202 766
Other Assets 20 -
Deferred policy acquisition costs 25 102
Operating lease right-of-use assets 34 43
Prepayment and other assets 105 150
Property and equipment, net 14 16
Total assets 19,965 8,053
Liabilities and Shareholders’ Equity
Liabilities:
Reserve for losses and loss adjustment expenses 91 91
Notes payable to noteholders 118 118
Premium payable 3 -
Unearned premiums reserve 230 926
Losses payable 73 73
Operating lease liabilities 34 43
Accounts payable and other liabilities 322 309
Total liabilities 871 1,560
Mezzanine Equity
Due to Cat Re / T20 / T42 tokenholders 560 518
100,000 HCI 2026 Series A tokens at redemption value of $36.31 per token 3,631 -
100,000 HCI 2026 Series B tokens at redemption value of $49.43 per token 4,943 -
100,000 HCI 2026 Series C tokens at redemption value of $35.51 per token 3,551 -
Total Mezzanine equity 12,685 518
Shareholders’ equity:
Ordinary share capital, (par value $0.001, 500,000,000 shares authorized; 8,178,577 and 7,664,122 shares issued and outstanding) 6 6
Additional paid-in capital 38,645 38,047
Accumulated Deficit (32,462) (32,137)
Total Oxbridge shareholders’ equity 6,189 5,916
Non-controlling interests 220 59
Total shareholders’ equity 6,409 5,975
Total liabilities, mezzanine and shareholders’ equity 19,965 8,053

Consolidated Statements of Cash Flows (Unaudited)

(expressed in thousands of U.S. Dollars)

Description Nine months ended September 30, 2026 Nine months ended September 30, 2025
Operating activities
Net loss attributable to ordinary shareholders (223) (2,199)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation 198 332
Realized gain on other investments - (35)
SurancePlus management fee income (501) (1)
Depreciation and amortization 2 -
Change in fair value of other investments - 20
Change in fair value of equity securities - (2)
Income (loss) attributable to non-controlling interests 164 (102)
Change in operating assets and liabilities:
Operating right-of-use asset (9) 78
Operating lease liabilities 9 (78)
Premiums receivable 564 (152)
Deferred policy acquisition costs 77 (54)
Other assets (20) -
Prepayment and other assets 45 (24)
Premium payable 3 -
Unearned premiums reserve (696) 490
Accounts payable and other liabilities 13 (54)
Net cash used in operating activities (374) (1,781)
Investing activities
Proceeds from sale of other investments - 63
Net cash provided by investing activities - 63
Financing activities
Proceeds from issuance (redemption) of Tokenholders 42 (524)
Proceeds from issuance of ordinary shares 400 3,525
Proceeds from issuance of HCI 2026 Series A, B & C Tokens 6,323 -
Proceeds from HCI Additional Collateral Deposit 6,198 -
Net cash provided by financing activities 12,963 3,001
Cash and cash equivalents, and restricted cash and cash equivalents:
Net change during the period 12,589 1,283
Balance at beginning of period 6,976 5,893
Balance at end of period 19,565 7,176
Non-cash investing and financing activities
Right-of-use lease asset obtained in exchange for operating lease liabilities 86 -
Reclassification of contributed non-controlling interest 3 104
Reclassification of other liabilities EpsilonCat Re / DeltaCat Re - 1,732
Remeasurement of carrying value of HCI 2026 Series tokens 105 -

Amounts as printed on the EDGAR/iXBRL face — (expressed in thousands of U.S. Dollars, except per share amounts); (expressed in thousands of U.S. Dollars, except per share and share amounts); (expressed in thousands of U.S. Dollars). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗